Morning Briefing
Summaries of health policy coverage from major news organizations
Research Roundup: The Latest Science, Discoveries, And Breakthroughs
Stat: Akeso And Summit’s Ivonescimab Extends Survival In Squamous Cell Lung Cancer
Ivonescimab, a drug that combines the activity of two of the best-selling cancer medicines, reduced the risk of death in patients with squamous non-small cell lung cancer by 34% compared to a standard treatment in a clinical trial conducted entirely in China by the drug’s developer, Akeso Therapeutics, according to data presented Sunday. The result, oncologists say, exceeded their expectations, and it appears it could generate optimism for the drug, which is being developed outside China by Summit Therapeutics. (Herper, 5/31)
MedPage Today: Novel Biologic Performs Well In IgG4-Related Disease
An investigational monoclonal antibody drug for immunoglobulin (Ig)G4-related disease called obexelimab substantially outperformed placebo in the phase III INDIGO trial, researchers reported, positioning it to take on the only drug now specifically approved for the condition. Time to first disease flare after starting therapy was more than halved with obexelimab, and twice as many patients obtained complete remission in the yearlong study, according to John Stone, MD, MPH, of Mass General Brigham in Boston, and colleagues. (Gever, 6/2)
MedPage Today: For Egg Allergy Oral Immunotherapy, Low-Dose Liquid May Be A Key To Success
For egg-allergic children, an oral immunotherapy (OIT) protocol using low-dose liquid egg to start appeared to be the most successful in inducing tolerance in the outpatient setting, according to one academic center's experience. (Phend, 6/3)
HealthDay: When Kids’ Lies Are Normal And When They May Signal Future Patterns
Most lying children will not grow up with criminal records or certain mental health diagnoses, a new study says. Occasional lying is common among kids and no cause for alarm, researchers reported May 27 in the journal Development and Psychopathology. (Thompson, 6/1)
CIDRAP: The Scent Of Supper: Can Mosquitoes Learn To Love DEET?
Research published in the Journal of Experimental Biology suggests that mosquitoes may learn to associate the smell of DEET with dinner—and start gravitating toward it instead of away from it. The findings challenge long-held assumptions about how DEET works and what mosquitoes may be capable of learning. (Bergeson, 5/29)
